Palliative primary tumor resection provides survival benefits for the patients with metastatic colorectal cancer and low circulating levels of dehydrogenase and carcinoembryonic antigen

Table 1 Summary of studies that evaluated the role of PPTR

First author and reference number	Period of patient involvement	Chemotherapy regimen	PPTR	No. of patients	Median OS (months)	P
Seo [4]	2001–2008	Oxaliplatin, irinotecan, and 5-FU	Yes	144	22	0.076
Seo [4]	2001–2008	Oxaliplatin, irinotecan, and 5-FU	No	83	14	0.076
Sabine [16]	2003–2004	Irinotecan, oxaliplatin, and capecitabine	Yes	258	16.7	<0.001
Sabine [16]	2003–2004	Irinotecan, oxaliplatin, and capecitabine	No	141	11.4	<0.001
Sabine [16]	2005–2006	Oxaliplatin and capecitabine	Yes	289	20.7	<0.001
Sabine [16]	2005–2006	Oxaliplatin and capecitabine	No	159	13.4	<0.001
Leyo [17]	1996–1999	Unknown	Yes	127	16	<0.001
Leyo [17]	1996–1999	Unknown	No	103	9	<0.001
Ferrand [18]	1997–2001	5-FU + CF, 5-FU, or raltitrexed	Yes	156	16.3	<0.001
Ferrand [18]	1997–2001	5-FU + CF, 5-FU, or raltitrexed	No	60	9.6	<0.001
Mehdi [19]	1998–2007	FOLFOX, FOLFIRI, XELOX, or 5-FU	Yes	85	30.7	0.031
Mehdi [19]	1998–2007	FOLFOX, FOLFIRI, XELOX, or 5-FU	No	123	21.9	0.031
Tebutt [20]	1990–1999	5-FU, raltitrexed, capecitabine, or uracil tegafur	Yes	280	14	0.080
Tebutt [20]	1990–1999	5-FU, raltitrexed, capecitabine, or uracil tegafur	No	82	8.2	0.080
Martyn [21]	1999–2006	Unknown	Yes	45	11	0.206
Martyn [21]	1999–2006	Unknown	No	52	7	0.206

PPTR palliative primary tumor resection, OS overall survival, 5-FU 5-fluorouracil, CF cisplatin and 5-fluorouracil, FOLFOX folinic acid 5-fluorouracil and oxaliplatin, FOLFIRI folinic acid, 5-fluorouracil, and irinotecan, XELOX xeloda and oxaliplatin

ISSN: 2523-3548